Clinical Trials Directory

Trials / Unknown

UnknownNCT03713736

Papillomavirus Load in Rheumatic Inflammatory Diseases

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
385 (estimated)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
Female
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are the two most common chronic inflammatory rheumatism, with a prevalence in the French population of 0.3% and 0.4%, according to the criteria European League Against Rheumatism / American College of Rheumatology (EULAR / ACR) 2010 and Assessemnt of SpondyloArthritis International Society (ASAS) 2009 respectively. In patients whose pathology is resistant to first-line treatment, such as methotrexate for rheumatoid arthritis and peripheral spondyloarthritis, or non-steroidal anti-inflammatory drugs for axial spondyloarthritis, the treatment is based on biotherapies, such as anti-inflammatory drugs. -TNF, to obtain effective control of the disease and prevent joint damage. Human papillomavirus (HPV) infection, the leading risk factor for cervical carcinoma, is the most common sexually transmitted infection (STI) with a particularly high prevalence among young women. In addition, anti-TNF, used in the treatment of RA and SpA, and anti-IL6 receptor, used in that of RA, could have opposite effects on HPV-dependent oncogenesis. Thus, patients with RA or SpA may have a higher risk than the general population of progression to cervical cytological abnormalities. Evaluation of the chronic carriage of HPV would then be a useful tool in the management of these patients.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTCervical smearCervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
DIAGNOSTIC_TESTPregnancy testUrinary pregnancy test
BEHAVIORALSexual activity questionnarySexual activity questionnary

Timeline

Start date
2020-01-09
Primary completion
2024-01-09
Completion
2024-01-09
First posted
2018-10-22
Last updated
2021-07-27

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03713736. Inclusion in this directory is not an endorsement.